|
Volumn 2, Issue 7, 2005, Pages 0583-0586
|
What can we learn from medical whistleblowers?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CYCLOOXYGENASE 2 INHIBITOR;
GABAPENTIN;
ROFECOXIB;
ADDICTION;
CARDIOVASCULAR DISEASE;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG INFORMATION;
DRUG MARKETING;
DRUG SAFETY;
E-MAIL;
FOOD AND DRUG ADMINISTRATION;
HEALTH HAZARD;
HUMAN;
MEDICAL INFORMATION;
MOOD DISORDER;
PATIENT ADVOCACY;
REVIEW;
ARTICLE;
CONFIDENTIALITY;
HEALTH SERVICES RESEARCH;
INSTITUTIONAL ETHICS;
MEDICAL ETHICS;
NATIONAL HEALTH SERVICE;
ORGANIZATION;
ORGANIZATION AND MANAGEMENT;
PERCEPTION;
PERSONNEL MANAGEMENT;
WHISTLEBLOWING;
CONFIDENTIALITY;
DRUG INDUSTRY;
EMPLOYEE DISCIPLINE;
ETHICS, INSTITUTIONAL;
ETHICS, MEDICAL;
HUMANS;
ORGANIZATIONAL CASE STUDIES;
ORGANIZATIONAL CULTURE;
SOCIAL PERCEPTION;
STATE MEDICINE;
WHISTLEBLOWING;
|
EID: 33846623262
PISSN: 15491277
EISSN: 15491676
Source Type: Journal
DOI: 10.1371/journal.pmed.0020209 Document Type: Review |
Times cited : (6)
|
References (11)
|